Peer Review
Cancer Imaging
ISSN 1470-7330
Search site with:PicoSearch


Content
Current Issue
Archive
Related Journals / Articles
Information
Aims and Scope
Editors and Board
Editorial Policy
Instructions for Authors
Copyright Transfer Form
Subscription Information
Advertising
Society
Aims
Membership
Annual Meeting
Communications
Send Email to ICIS
e-Med
Visit e-Med Web Site
Journals
Purchase
“To Promote Education in Cancer Imaging in the Multidisciplinary Management of Malignancy”

Home > Articles

Thermal ablation of hepatocellular carcinoma Open Access Article

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of hepatitis B and C virus infection. Patients with cirrhosis are at the highest risk of developing HCC and should be monitored every 6 months to diagnose the tumour at an early, asymptomatic stage. Patients with early-stage HCC should be considered for any of the available curative therapies, including surgical resection, liver transplantation and percutaneous image-guided ablation. Liver transplantation is the only option that provides cure of both the tumour and the underlying chronic liver disease. However, the lack of sufficient liver donation greatly limits its applicability. Resection is the treatment of choice for HCC in non-cirrhotic patients, who account for about 5% of the cases in western countries. However, in patients with cirrhosis, candidates for resection have to be carefully selected to reduce the risk of postoperative liver failure. It has been shown that a normal bilirubin concentration and the absence of clinically significant portal hypertension are the best predictors of excellent outcomes after surgery. However, less than 5% of cirrhotic patients with HCC fit these criteria. Image-guided percutaneous ablation is the best therapeutic choice for non-surgical patients with early-stage HCC. While ethanol injection has been the seminal percutaneous technique, radiofrequency ablation has emerged as the most effective method for local tumour destruction and is currently used as the primary ablative modality at most institutions.

Author

Laura Crocetti and Riccardo Lencioni

Contact Details

Corresponding address:
Laura Crocetti, Division of Diagnostic and Interventional Radiology,
University Hospital, Via Roma 67, IT-56126 Pisa, Italy

Reference

ICIS Cancer Imaging Volume 8 Issue 1
DOI: 10.1102/1470-7330.2008.0004

Date Posted

27 February 2008


Open Access Article Open Access is provided for this article.

Print PDF

Size

2.53 MB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):

10 seconds

ADSL 512Kb/s (Broadband):

40 seconds

64 Kb/s (ISDN):

5 minutes 23 seconds

33.3 Kb/s (Typical Modem):

10 minutes 22 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 66356, London, E14 1GW. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.

© 2000-2010 International Cancer Imaging Society